Trexquant Investment LP Sells 30,796 Shares of Aligos Therapeutics, Inc. $ALGS

Key Points

• Trexquant Investment LP reduced its stake in Aligos Therapeutics by 44.6%, selling 30,796 shares and now holding 38,254 shares worth $316,000 as per its latest SEC filing.
• HC Wainwright has initiated coverage on Aligos Therapeutics with a buy rating and a target price of $50.00.
• Aligos Therapeutics recently reported better-than-expected earnings with a loss of ($1.53) per share, beating the consensus estimate of ($2.35).

Trexquant Investment LP decreased its position in Aligos Therapeutics, Inc. (NASDAQ:ALGS - Free Report) by 44.6% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 38,254 shares of the company's stock after selling 30,796 shares during the period. Trexquant Investment LP owned about 0.63% of Aligos Therapeutics worth $316,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of the company. Heights Capital Management Inc. bought a new stake in Aligos Therapeutics in the 1st quarter valued at approximately $1,992,000. AlphaQuest LLC acquired a new stake in shares of Aligos Therapeutics in the 1st quarter valued at approximately $130,000. Readystate Asset Management LP acquired a new stake in shares of Aligos Therapeutics in the 1st quarter valued at approximately $375,000. Golden State Wealth Management LLC boosted its holdings in shares of Aligos Therapeutics by 100.0% in the 1st quarter. Golden State Wealth Management LLC now owns 5,348 shares of the company's stock valued at $44,000 after buying an additional 2,674 shares during the last quarter. Finally, Northern Trust Corp acquired a new stake in shares of Aligos Therapeutics in the 4th quarter valued at approximately $205,000. Institutional investors own 60.43% of the company's stock.

Aligos Therapeutics Stock Performance

ALGS traded down $0.83 during trading hours on Monday, reaching $9.37. The company's stock had a trading volume of 94,063 shares, compared to its average volume of 70,577. Aligos Therapeutics, Inc. has a 52 week low of $3.76 and a 52 week high of $46.80. The company's 50-day moving average is $9.17 and its 200-day moving average is $7.94. The firm has a market cap of $57.63 million, a PE ratio of -0.47 and a beta of 2.79.

Aligos Therapeutics (NASDAQ:ALGS - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($1.53) earnings per share for the quarter, beating analysts' consensus estimates of ($2.35) by $0.82. Aligos Therapeutics had a negative return on equity of 22.41% and a negative net margin of 2,337.24%.The business had revenue of $0.97 million for the quarter, compared to analysts' expectations of $0.43 million. Equities analysts anticipate that Aligos Therapeutics, Inc. will post -10.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a "buy" rating and issued a $50.00 price objective on shares of Aligos Therapeutics in a report on Friday. One analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, Aligos Therapeutics currently has an average rating of "Buy" and an average price target of $50.00.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).